NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05721950 2026-02-18
Brilliant
Takeda
Active not recruiting
NCT04223596 2026-02-04
CUBIK
Fundación GECP
Phase 2 Active not recruiting
NCT04374305 2026-01-12
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Active not recruiting